Day: April 29, 2025

The supervisory board of AS Trigon Property Development approved on 29th of April 2025 the audited annual report and profit allocation proposal for the year 2024. The supervisory board decided to present the annual report and profit allocation proposal as prepared by the management for the approval of the general meeting of shareholders. The revenues and profits remained unchanged compared to the preliminary disclosure on 20 February 2025. The original audited Annual Report 2024 document is submitted in machine-readable .xhtml format to the Nasdaq Tallinn Stock Exchange and digitally signed (Link: https://nasdaqbaltic.com/statistics/et/instrument/EE3100003443/reports). The audited Annual Report of AS Trigon Property Development for 2024 in pdf-format without European Single Electronic Format (ESEF) markups is available on issuer’s home...

An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safety These findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an exposure-outcome analysis of its innate cell engager (ICE®) AFM24, in patients with advanced or metastatic non-small cell lung cancer (NSCLC)...

Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced the presentation of new preclinical data from two of its lead programs at the American Association for Cancer Research (AACR) Annual Meeting 2025. The first presentation highlighted Rakovina’s PARP1-selective inhibitor program. Using the proprietary Deep Docking and generative platforms , Rakovina previously screened more than four billion potential drug-like molecules to identify a shortlist of top candidates. These compounds were synthesized and...

Kalmar Ottawa AutoTT, an autonomous terminal tractorKalmar Ottawa AutoTT, an autonomous terminal tractor is undergoing its second round of testingOTTAWA, KANSAS, April 29, 2025 (GLOBE NEWSWIRE) — Today, Kalmar, a leader in terminal tractor solutions, and autonomous systems provider, Forterra unveiled the Kalmar Ottawa AutoTT™, an autonomous terminal tractor designed to improve efficiency and safety in distribution centers, container terminals, and industrial yards. The AutoTT™ is currently undergoing its second round of testing as Kalmar moves closer to bringing it to market, with full production anticipated by late 2026.  The partnership between Kalmar and Forterra, established in March 2024, brings together Kalmar’s expertise and leadership in terminal tractors with Forterra’s AutoDrive®, an advanced autonomous...

West Palm Beach, April 29, 2025 (GLOBE NEWSWIRE) — FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), today announced that effective 4.01pm Eastern Time, on April 28, 2025, (the “Effective Time”), the Company completed a 1 for 10 reverse stock split of its outstanding common stock. The Company’s common stock will open for trading on Tuesday April 29, 2025, on a post-split basis and continue to trade under the symbol FOXO. As a result of the reverse split, every 10 shares of the Company’s common stock issued and outstanding on the Effective Time will be consolidated into one issued and outstanding share with no change in the nominal par value per share of $0.0001. No fractional shares will be outstanding following the Reverse Stock Split. Holders of fractional shares will be entitled to receive, in lieu of any...

The rating agency Moody’s Investors Service affirmed AS LHV Pank’s and AS LHV Group’s raitings, leaving LHV Pank’s long-term deposit rating to A3 level (with positive outlook) and LHV Group’s long-term issuer rating to Baa3 (with a positiive outlook). These ratings indicate LHV’s strong financial position and capitalization as well as express the expectation of further strengthening of solidity. Moody’s has assigned AS LHV Group long-term issuer ratings:Long-term issuer rating Baa3 Senior unsecured rating Baa3 Outlook of the ratings is positiveMoody’s affirmed the raitings assigned to AS LHV Pank:Long- and short-term counterparty risk assessment of A3(cr)/Prime-2(cr) Long- and short-term counterparty risk rating of A3/Prime-2 Long-term bank deposit rating A3 Short-term bank deposit rating Prime-2 The long-term...

ENGLEWOOD, Colo., April 29, 2025 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) announced today that it will host a conference call on May 13, 2025, at 4:30 p.m. ET (2:30 p.m. MT) to report its financial results for the first quarter ended March 31, 2025. To participate in the live call, please register through the following event weblink: https://register-conf.media-server.com/register/BI14d4db26011d45b9871ce05b8b3c5a63   After registering, participants will be provided with a dial-in number and pin. To listen to the conference call (audio only), please register through the following event weblink: https://edge.media-server.com/mmc/p/xd9v2i3x   A webcast replay will be available two hours after the conference call ends on May 13, 2025. The archived webcast will be available in the Investor Relations section of Gevo’s website...